Pharmaceutical Product Monograph: The “Cardiac Triple” Capsule
In the pharmaceutical industry, the combination of Aspirin (75 mg), Atorvastatin (20 mg), and Clopidogrel (75 mg) is known as a Fixed-Dose Combination (FDC) Polypill. As a pharmacist and manufacturer, I view this as a “Comprehensive Vascular Protection” unit—it is technically designed to address three distinct pathways of cardiovascular disease in a single daily dose.
At your WHO-GMP facility in Mumbai, this is a high-value Secondary Prevention SKU. It is primarily prescribed for patients who have already suffered a myocardial infarction (heart attack), a stroke, or have undergone a stent procedure (PCI).
Therapeutic Profile: The Triple-Action Mechanism
This capsule functions as a “three-in-one” defense system against the recurrence of major adverse cardiovascular events (MACE).
| Component | Class | Technical Function |
| Aspirin (75 mg) | Antiplatelet (NSAID) | Irreversibly inhibits COX-1, preventing the formation of Thromboxane $A_2$ to stop platelets from sticking together. |
| Clopidogrel (75 mg) | Antiplatelet (P2Y12) | A prodrug that binds to the P2Y12 receptor, blocking a different pathway of platelet aggregation than Aspirin. |
| Atorvastatin (20 mg) | HMG-CoA Reductase Inhibitor | Reduces “Bad Cholesterol” (LDL) and stabilizes existing arterial plaques, preventing them from rupturing. |
Clinical Indications: When is it Used?
Post-Myocardial Infarction: To prevent a second heart attack.
Post-Stroke / TIA: To reduce the risk of a recurrent ischemic stroke.
Peripheral Artery Disease (PAD): To improve blood flow and prevent limb-threatening clots.
Post-Stenting (PCI): To prevent “Stent Thrombosis” (where a clot forms inside the newly placed stent).
The Pharmacist’s “Technical Warning”
The “Bleeding” Cluster: Because this is Dual Antiplatelet Therapy (DAPT) plus a statin, the risk of bruising, nosebleeds, and gastrointestinal bleeding is significantly higher than with a single drug.
Muscle Safety (Myopathy): Atorvastatin can occasionally cause muscle pain or weakness. If the patient notices dark, tea-colored urine, they must stop the drug immediately as it may indicate Rhabdomyolysis.
The “Liver” Check: Baseline and periodic Liver Function Tests (LFTs) are technically required due to the Atorvastatin component.
The “Grapefruit” Rule: Patients must avoid grapefruit juice, as it inhibits the CYP3A4 enzyme, leading to potentially toxic levels of Atorvastatin in the blood.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at Healthy Life Pharma / Healthy Inc:
The “Stability” Challenge: Clopidogrel and Aspirin are chemically sensitive to moisture (hygroscopic). On your digital marketplace, highlight your Alu-Alu Blistering. This is a non-negotiable technical requirement for B2B export to tropical “Zone IVb” regions to ensure the capsule remains stable.
The “Adherence” USP: Market this as a “Patient Compliance Solution.” Statistics show that patients are $40\text{–}50\%$ more likely to stick to their treatment when taking one “Polypill” versus three separate tablets. This is a massive selling point for international hospital tenders.
Enteric Coating (EC): For a premium B2B offering, ensure the Aspirin component is Enteric Coated. This allows it to pass through the stomach and dissolve in the intestine, significantly reducing the risk of gastric ulcers—a major concern for long-term cardiac patients.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers including “Triple-Drug Stability Studies” to support your registration in regulated international markets.